In The News
Merger regime overhaul to make process more challenging, lawyers say
ASIC challenges court’s exemption finding despite win in crypto case
AFT’s patent for cold medication just three drugs ‘in a box’, IP Australia says
With new self-funding model, class action firm’s promise to pay Macquarie’s costs not enough
Solicitors can stay on case against Super Retail despite conflict of interest
Court stays Clive Palmer’s challenge to ASIC examination
Class action lodged in High Court on behalf of South Sudanese refugees
Rugby Australia hit with legal action by Melbourne Rebels
NSW to face expanded class action over correctional officer’s abuse
Jaguar hits back at diesel filter class action
Please login to bookmarkClose

Korean drug company Samsung Bioepis has filed a lawsuit seeking to invalidate German drug company Fresenius Kadi’s patent for a biosimilar of blockbuster arthritis drug Humira.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?
Lost your password?

Contact us to enquire about group subscriptions.
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au